Sugi Predict

Sugi Predict / Compounds / SCHEMBL669236

SCHEMBL669236

SCHEMBL669236

NCC1(CN2CCCC2)CC1

nearest known ligand 0.33

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.33
▸ LMNA P02545 2/20 0.31
▸ USP2 O75604 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ BLM P54132 1/20 0.31
▸ CACNA2D1 P54289 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ SLC6A2 P23975 2/20 0.30
▸ SLC6A4 P31645 2/20 0.30
▸ SLC6A3 Q01959 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16827165 0.83 HRH3 (0.33) SMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL13820190 0.79 SLC6A2 (0.34) LMNASMN1; SMN2SLC6A2SLC6A4
SCHEMBL13820147 0.79 SMN1; SMN2 (0.43) LMNAUSP2ALDH1A1TSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL22401325 0.78 KDM4E (0.44) LMNAUSP2ALDH1A1TSHRSMN1; SMN2
SCHEMBL951043 0.75 MAPT (0.34) KDM1ALMNATSHRSLC6A2SLC6A4
SCHEMBL12717841 0.75 KDM1A (0.33) KDM1ALMNATSHRSLC6A2SLC6A4
SCHEMBL16292405 0.74 SLC6A2 (0.41) LMNAUSP2ALDH1A1CYP1A2TSHR
SCHEMBL12717855 0.73 HRH3 (0.33) KDM1ATSHRSLC6A2SLC6A4SLC6A3
SCHEMBL22725319 0.73 MEN1 (0.36) KDM1ALMNAALDH1A1CYP1A2TSHR
Hydrochloric Acid SCHEMBL948609 0.73 LMNA (0.35) KDM1ALMNATSHRSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257057-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.I. (IT) 2025-08-14 — — US disclosed
US-12258337-B2 Bicyclic CX3CR1 receptor agonists BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-03-25 — — US disclosed
CN-113874374-B Hydrogenated pyridopyrimidine derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-12-27 — — CN disclosed
CN-114929681-B Bicyclic CX3CR1 receptor agonists 德州大学系统董事会 2024-05-14 — — CN disclosed
US-20240150332-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.L. (IT) 2024-05-09 — — US disclosed
US-11958839-B2 Bicyclic CX3CR1 receptor agonists BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-16 — — US disclosed
WO-2022266015-A1 FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS KUMQUAT BIOSCIENCES INC. (US) 2022-12-22 — — WO disclosed
CN-114929681-A Bicyclic CX3CR1 receptor agonists 德州大学系统董事会 2022-08-19 — — CN disclosed
US-20220259191-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.L. (IT) 2022-08-18 — — US disclosed
EP-4003972-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS Board of Regents, The University of Texas System (US) 2022-06-01 — — EP disclosed
US-20120093767-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 — — US disclosed
WO-2012024373-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 — — WO disclosed
WO-2011139513-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 — — WO disclosed
WO-2011139513-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 — — WO disclosed
US-7709471-B2 Compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
EP-2046793-A2 FUSED PYRIMIDO COMPOUNDS AstraZeneca AB (SE) 2009-04-15 — — EP disclosed
WO-2008040951-A1 COMPOUNDS ASTRAZENECA AB (SE) 2008-04-10 — — WO disclosed
WO-2008040951-A1 COMPOUNDS ASTRAZENECA AB (SE) 2008-04-10 — — WO disclosed
WO-2008003958-A2 FUSED PYRIMIDO COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 — — WO disclosed
US-20080009482-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258337-B2 Bicyclic CX3CR1 receptor agonists CX3CR1, CCR2, CCR5 KDM1A 4779/4885LMNA 3542/4885USP2 4685/4885
US-20120093767-A1 Compounds for the Treatment of Hepatitis C HAVCR2, SLC10A1, HCCS KDM1A 4539/4885LMNA 3006/4885USP2 3451/4885
US-20220259191-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS CX3CR1, CCR2, CCR5 KDM1A 4779/4885LMNA 3542/4885USP2 4685/4885
US-20080009482-A1 NOVEL COMPOUNDS CYP11B2, CYP11B1, CYP46A1 KDM1A 4397/4885LMNA 1996/4885USP2 4608/4885
US-20250257057-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS CX3CR1, CCR2, CCR5 KDM1A 4779/4885LMNA 3542/4885USP2 4685/4885
US-11958839-B2 Bicyclic CX3CR1 receptor agonists CX3CR1, CCR2, CCR5 KDM1A 4779/4885LMNA 3542/4885USP2 4685/4885
US-20240150332-A1 BICYCLIC CX3CR1 RECEPTOR AGONISTS CX3CR1, CCR2, CCR5 KDM1A 4779/4885LMNA 3542/4885USP2 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.